NLS Pharmaceutics Ltd (NLSP)
0.1494
0.00 (0.00%)
USD |
NASDAQ |
May 16, 16:00
0.155
+0.01
(+3.75%)
After-Hours: 20:00
NLS Pharmaceutics Enterprise Value
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 15, 2024 | 4.673M |
| May 14, 2024 | 4.886M |
| May 13, 2024 | 4.435M |
| May 10, 2024 | 4.383M |
| May 09, 2024 | 4.478M |
| May 08, 2024 | 4.353M |
| May 07, 2024 | 4.409M |
| May 06, 2024 | 4.240M |
| May 03, 2024 | 4.327M |
| May 02, 2024 | 4.240M |
| May 01, 2024 | 4.149M |
| April 30, 2024 | 4.400M |
| April 29, 2024 | 4.485M |
| April 26, 2024 | 4.270M |
| April 25, 2024 | 4.084M |
| April 24, 2024 | 3.764M |
| April 23, 2024 | 3.989M |
| April 22, 2024 | 3.976M |
| April 19, 2024 | 4.097M |
| April 18, 2024 | 4.097M |
| April 17, 2024 | 4.110M |
| April 16, 2024 | 4.283M |
| April 15, 2024 | 4.478M |
| April 12, 2024 | 4.829M |
| April 11, 2024 | 5.000M |
| Date | Value |
|---|---|
| April 10, 2024 | 4.829M |
| April 09, 2024 | 4.816M |
| April 08, 2024 | 4.439M |
| April 05, 2024 | 4.509M |
| April 04, 2024 | 5.029M |
| April 03, 2024 | 5.280M |
| April 02, 2024 | 5.969M |
| April 01, 2024 | 5.817M |
| March 28, 2024 | 6.146M |
| March 27, 2024 | 5.501M |
| March 26, 2024 | 5.921M |
| March 25, 2024 | 5.518M |
| March 22, 2024 | 6.146M |
| March 21, 2024 | 4.519M |
| March 20, 2024 | 4.051M |
| March 19, 2024 | 8.133M |
| March 18, 2024 | 8.148M |
| March 15, 2024 | 9.572M |
| March 14, 2024 | 10.51M |
| March 13, 2024 | 10.75M |
| March 12, 2024 | 9.050M |
| March 11, 2024 | 10.33M |
| March 08, 2024 | 9.342M |
| March 07, 2024 | 9.861M |
| March 06, 2024 | 9.828M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
3.764M
Minimum
Apr 24 2024
70.97M
Maximum
Mar 12 2021
22.75M
Average
21.39M
Median
Aug 13 2021
Enterprise Value Benchmarks
| AC Immune SA | 221.07M |
| CRISPR Therapeutics AG | 2.619B |
| Addex Therapeutics Ltd | 5.016M |
| Molecular Partners AG | -100.61M |
| MoonLake Immunotherapeutics | 2.021B |